1-8 of 8
flt3 inhibitors
Close
Sort by
Journal Articles

ETV6-FLT3– positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML

Clinical Trials & Observations
Barbara Spitzer, Filemon S. Dela Cruz, Glorymar D. Ibanez Sanchez, Yanming Zhang, Wenbin Xiao, Ryma Benayed, Alina Markova, M. Irene Rodriguez-Sanchez, Nancy Bouvier, Mikhail Roshal, Andrew L. Kung, Neerav Shukla
Journal: Blood Advances
Blood Adv (2021) 5 (7): 1899–1902.
https://doi.org/10.1182/bloodadvances.2020003699
Published: 2021
Journal Articles

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Olga Frankfurt, John M. Pagel, Gail J. Roboz, Richard M. Stone, Eunice S. Wang, Paul L. Severson, Brian L. West, Mai H. Le, Sabine Kayser, Bao Lam, Henry H. Hsu, Chao Zhang, Gideon Bollag, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1711–1721.
https://doi.org/10.1182/bloodadvances.2020001449
Published: 2020
Includes: Supplemental data
Journal Articles

Quizartinib-resistant FLT3 -ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736

Andrew S. Moore, Amir Faisal, Grace W. Y. Mak, Farideh Miraki-Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, Randal Stronge, Andrew D. J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David C. Taussig, Spiros Linardopoulos
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1478–1491.
https://doi.org/10.1182/bloodadvances.2019000986
Published: 2020
Includes: Supplemental data
Journal Articles

Gilteritinib: potent targeting of FLT3 mutations in AML

Clinical Trials & Observations
Mark Levis, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1178–1191.
https://doi.org/10.1182/bloodadvances.2019000174
Published: 2020
Journal Articles

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Clinical Trials & Observations
Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2020) 4 (3): 514–524.
https://doi.org/10.1182/bloodadvances.2019000919
Published: 2020
Includes: Supplemental data
Journal Articles

Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia

Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E. Perl, Martin Carroll
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1061–1072.
https://doi.org/10.1182/bloodadvances.2018029850
Published: 2019
Includes: Supplemental data
Journal Articles

The role of targeted therapy in the management of patients with AML

Clinical Trials & Observations
Alexander E. Perl
Journal: Blood Advances
Blood Adv (2017) 1 (24): 2281–2294.
https://doi.org/10.1182/bloodadvances.2017009829
Published: 2017
Journal Articles

The current therapeutic landscape of FLT3 inhibitors

Mark Levis
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1944.
https://doi.org/10.1182/bloodadvances.2017007682
Published: 2017
Includes: Supplemental data